Parthenolide inhibits the initiation of experimental autoimmune neuritis

J Neuroimmunol. 2017 Apr 15:305:154-161. doi: 10.1016/j.jneuroim.2017.02.003. Epub 2017 Feb 8.

Abstract

A growing body of evidence suggests the anti-inflammatory and antitumor effects of parthenolide (PAR). Here we show that PAR treatment inhibits the initiation of experimental autoimmune neuritis (EAN), suppresses the production of TNF-α, IFN-γ, IL-1β and IL-17, and decreases Th1 and Th17 cells at early time point. However, such anti-inflammatory effect vanishes later and PAR impedes the recovery of EAN in late phase, which is accompanied with inhibited apoptosis of inflammatory cells. Our results indicate that PAR plays dual roles in EAN and it is not proper to be applied in autoimmune diseases of nervous system.

Keywords: Apoptosis; Cytokines; Experimental autoimmune neuritis; Lymphocyte proliferation; Parthenolide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Annexin A5 / metabolism
  • Anti-Inflammatory Agents / therapeutic use*
  • Apoptosis / physiology
  • CD4-Positive T-Lymphocytes / pathology
  • Cell Proliferation / drug effects
  • Cell Proliferation / physiology
  • Cytokines / metabolism
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Flow Cytometry
  • Forkhead Box Protein O3 / metabolism
  • Freund's Adjuvant / toxicity
  • Lymph Nodes / pathology
  • Mycobacterium tuberculosis
  • Neuritis, Autoimmune, Experimental / drug therapy*
  • Neuritis, Autoimmune, Experimental / etiology
  • Rats
  • Rats, Inbred Lew
  • Sciatic Nerve / pathology
  • Sesquiterpenes / therapeutic use*

Substances

  • Annexin A5
  • Anti-Inflammatory Agents
  • Cytokines
  • Forkhead Box Protein O3
  • Sesquiterpenes
  • parthenolide
  • Freund's Adjuvant